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 Introduction
 The technique of systematic random prostate biopsy 
is still under debate since being described by Hodge et al. 
 [1]  20 years ago. As the potential of overlooking clini-
cally significant cancer has been reported in up to 30% 
of cases involving traditional sextant biopsy  [2] , more 
extended biopsy techniques are advocated today. Most 
patients with a negative first biopsy undergo at least one 
rebiopsy. After two sets of ten or more negative core bi-
opsies it seems that the risk of missing/overlooking can-
cer in patients with stable PSA levels  [3] is acceptably 
low. Particularly in those patients with rising PSA levels, 
multiple biopsies are often performed without prostate 
cancer (PCa) being detected. For such patients, trans-
urethral resection of the prostate (TURP) has been pro-
posed to diagnose PCa that is presumably located in the 
transitional zone. The detection rate of PCa via ‘diagnos-
tic TURP’ is as low as 18% in unselected patients  [4] . 
However, few data support such an approach in prese-
lected patients with a history of negative transrectal bi-
opsies.
 Vallancien et al.  [5] reported a decrease of urinary 
catheterization time and an improved post-treatment 
urinary status without additional morbidity in patients 
undergoing TURP before high-intensity focused ultra-
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 Abstract
 Introduction: The aim of our study was to evaluate the sig-
nificance of transurethral resection of the prostate (TURP) to 
detect prostate cancer (PCa). A comparison was performed 
of the TURP specimens of patients undergoing high-intensi-
ty focused ultrasound (HIFU) with the core biopsies. Materi-
als and Methods: TURP before undergoing HIFU therapy 
was performed in 106 patients without neoadjuvant treat-
ment. The resected tissue was subjected to histopathologi-
cal evaluation and compared to the histological results of 
transrectal prostate biopsy. Results: Cancer was detected in 
the resected tissue of 69 patients (65%). A positive correla-
tion of the amount of resected tissue and detection of PCa 
could be demonstrated in a multivariate analysis. Conclu-
sions: With a rate of 65% PCa detected by TURP, our data 
provide evidence that TURP might be suitable to detect PCa 
in a small group of selected patients with continuously rising 
PSA levels and several negative biopsies. On the other hand, 
these data underline/reinforce the necessity to treat the 
whole gland using modern treatment modalities such as 
HIFU and cryotherapy.  Copyright © 2013 S. Karger AG, Basel
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sound (HIFU) for localized PCa versus HIFU alone. At 
our institution, HIFU has been routinely combined with 
TURP since 2001. This group of patients offers a unique 
pool of histopathological material of core biopsies and 
prostate tissue from TURP in patients with proven PCa.
 The aim of this retrospective study was to investigate 
the potential of TURP in detecting PCa in patients with 
diagnosed PCa and to analyze factors predicting a posi-
tive histology from TURP.
 Materials and Methods
 Between April 2001 and April 2006, 184 patients with clini-
cally localized PCa were treated with TURP before undergoing 
HIFU therapy in our department. TURP was performed as in be-
nign prostatic hyperplasia (BPH) cases by resecting the whole tran-
sitional zone. For histopathological evaluation, the total resected 
tissue was processed and investigated by the pathologist.
 An indication for the patients to undergo prostatic biopsy was 
given due to elevated serum PSA, abnormal digital rectal examina-
tion (DRE) or abnormal transrectal ultrasonography (TRUS) alone. 
The patients received a TRUS-guided needle biopsy with at least two 
cores taken from each lobe. Four to 12 cores were taken at prostate 
biopsy. Patients with DRE abnormalities were evaluated carefully by 
TRUS for corresponding lesions. Total prostate volume was calcu-
lated: (antero-posterior diameter × transverse diameter × longitudi-
nal diameter) × 0.60. Biopsy material was obtained using an auto-
matic biopsy gun with an 18-gauge Tru-Cut. The histopathological 
evaluation of prostate biopsies was following standard procedures 
according to published guidelines  [6] . All biopsies were processed 
separately and at least six serial section levels were investigated. 
Grading was done according the Gleason system in TURP speci-
mens and biopsies. Because all biopsies were investigated before the 
publication of the currently used modification of the Gleason score 
(GS) system  [7] , this system was not used in the present study.
 To eliminate a potential bias, we excluded the 78 patients (42%) 
who had received a previous hormone therapy. Statistical analysis 
was performed only for the 106 patients who had not received neo-
adjuvant treatment prior to biopsy and TURP.
 Statistical analyses were performed using the SPSS software 
version 17.0 (SPSS, Inc., Chicago, Ill., USA). The differences be-
tween two dependent variables were tested using the two-sided 
non-parametric Mann-Whitney U test. A multivariate Cox pro-
portional hazards regression model was used to estimate the prog-
nostic relevance of prostate volume, volume resected, PSA, clinical 
stage, number of samples with carcinoma and neoadjuvant hor-
monal therapy on cancer detection by TURP. p values <0.05 were 
considered statistically significant.
 Results
 Patients’ baseline characteristics are given in  table 1 . 
The median time between the TRUS-guided core biopsy 
and TURP was 1 month (range 0–9). The median prostate 
volume before TURP was 32 ml (range 14–72). The mean 
weight of the resected prostatic tissue was 16.3 ± 8.5 g. In 
patients where PCa could be verified by TURP, median 
10% (range 1–80%) of the resected prostatic specimen 
was infiltrated by tumor. There was no positive correla-
tion between prostatic volume and PCa detected by 
TURP. All patients had undergone at least one preopera-
tive TRUS-guided core biopsy. The distribution of pa-
tients according to age, prostate size and amount of re-
sected tissue was statistically not significantly different in 
the group with PCa-positive TURP and negative TURP.
 PCa was detected by biopsy in the right lobe in 27 
(25.5%) patients and in the left lobe in 45 (42.5%) pa-
tients. 29 (27.3%) patients had positive biopsy cores on 
both sides of the prostate. In 5 (4.7%) of the patients, no 
information is available concerning the side of the posi-
tive biopsy core. In patients with positive TURP, the 
number of patients with positive biopsy cores in both 
lobes was not significantly higher, being 29.0% (20 of 69 
patients).
 The mean PSA level before TURP was 8.6 ± 4.3 ng/ml. 
Mean PSA in patients with positive TURP and in patients 
with negative TURP was 7.3 ± 3.7 and 9.2 ± 4.5 ng/ml, 
respectively. In patients with a high PSA >10 ng/ml, PCa 









 Clinical staging, %
 T1 T2a T2b T3
All patients 184 68.2 ± 6.5 10.0 ± 8.3 33.6 ± 12.0 17.3 ± 9.4 28.2 46.3 20.3 1.6
With hormonal therapy 78 67.4 ± 5.6 11.8 ± 11.6 33.9 ± 13.9 18.6 ± 10.3 36.9 38.8 19.4 2.9
Without hormonal therapy 106 68.6 ± 6.8 8.6 ± 4.3 33.4 ± 9.4 16.3 ± 8.5 16.3 56.8 21.6 1.4
p value n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s.
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could be detected significantly more often than in pa-
tients with low PSA <10 ng/ml (p = 0.033).
 Overall, PCa was detected in the resected prostatic tis-
sue of TURP in 69 patients (65%). Out of these patients, 
30 (28.3%) had a GS <6, 28 (26.4%) had a GS of 6 or 7, and 
4 (3.8%) showed a high GS of 8–10. In 7 cases the histo-
logical differentiation was not specified ( table 2 ).
 Median GS in TURP specimens was 5.7 ± 1.3 com-
pared to the median GS of 5.3 ± 1.4 in the core biopsy
(p = 0.357). The GS was higher in the TURP specimens 
compared to the tissue of the prostate core biopsy in 29 
patients (48%), the same as in 17 patients (28%), and low-
er in 14 patients (23%). There was no significant correla-
tion between a low or medium GS in biopsy and cancer 
detection by TURP (p = 0.068), neither was it possible to 
demonstrate a statistically significant correlation between 
positive TURP and prostate size or number of positive 
cores (p = 0.80; p = 0.87). No correlation could be found 
between the localization of the positive core biopsies 
(right lobe, left lobe or both lobes) and a positive TURP 
(p = 0.67). It was, however, possible to demonstrate a pos-
itive correlation of the amount of resected tissue and de-
tection of PCa by TURP. It was possible to evaluate this 
significance in a univariate (p = 0.035) and a multivariate 
analysis (p = 0.044) ( table 3 ).
 78 (42%) of the patients received short-term hormon-
al therapy prior to TURP and HIFU treatment. Hormon-
al therapy had no significant influence on the amount of 
PCas diagnosed in the tissue obtained via TURP.
 Conclusions
 TRUS-guided biopsy is the gold standard in PCa detec-
tion. The chance of detecting PCa decreases after each neg-
ative biopsy set. In the European Prostate Cancer Detection 
Study, the incidence of detecting PCa was 22% in patients 
with a PSA value ranging from 4 to 10 ng/ml. The second 
round of biopsies in this large study detected an additional 
10% of cancers. The chance of finding PCa after the second 
biopsy decreases dramatically  [3] . There is evidence that 
saturation biopsies are helpful to detect PCa in patients 
where multiple sets of biopsies have failed. Kawakami et al. 
 [8] were able to diagnose PCa in 37% of patients with prior 
negative biopsies by combining transrectal and perineal bi-
opsies taken at the same time. Literature on PCa detection 
by TURP is rare, therefore the indication for a surgical ap-
proach suitable to detect cancer remains unclear.
 Ornstein et al.  [9] reviewed patients who had symp-
tomatic obstructive BPH with associated elevated PSA 
levels or suspicious DRE and a history of at least one be-
nign prostate biopsy. This group detected cancer in 16.1% 
of the TURP specimens. In unselected patients, TURP was 
responsible for the detection of 10% of all new PCa cases 
in the Utah Cancer Registry  [10] in the late 1990s. Niesel 
et al.  [11] investigated patients with BPH undergoing
simultaneous TURP and biopsy and found that in 27 
(19.7%) of 132 patients, the TURP specimens and biopsies 
were positive for cancer. Cancer was detected by biopsy 
alone in only 1 of 27 cases. However, carcinoma was found 
by TURP alone in 11 out of 132 patients. It is, however, 
important to note that patients with BPH were examined.
 In contrast to the existing data, our study demonstrat-
ed that the incidence of PCa detected by TURP is higher 
(65%) than estimated if carcinoma is present in the pros-
tate gland. The difference may stem from the initial clin-
ical profiles of patients who were studied. To the best of 
our knowledge, all previously published studies looked at 
the PCa detection rate of TURP in patients with unknown 
course of increased PSA levels. In contrast, our study in-
vestigates the value TURP to detect cancer in a prostate 
gland with biopsy-proven PCa.
Table 2.  GS of biopsy and of TURP specimens
Biopsy TURP
GS <6 49 (46.2%) 30 (28.3%)
GS 6 + 7 50 (47.2%) 28 (26.4%)
GS >7 2 (1.9%) 4 (3.8%)
No GS 5 (4.7%) 7 (6.6%)
Medium GS sum 5.3 ± 1.4 5.7 ± 1.3 p = 0.357
Table 3.  Multivariate analysis of factors affecting cancer detection 
by TURP
Parameters Hazard ratio 95% CI p value
PSA 1.027 0.977 – 1.079 0.296
Resected tissue 0.945 0.895 – 0.998 0.044
Prostate volume 0.995 0.956 – 1.035 0.806
Number of cores taken 0.988 0.841 – 1.160 0.879
T stage
T1a reference reference reference
T1b 0.000 0.974
T1c 1.860 0.185 – 18.679 0.598
T2a 2.423 0.315 – 18.647 0.395
T2b 1.050 0.114 – 9.699 0.966
Neoadjuvant hormonal/

















































 Therefore, our results are not comparable with previ-
ous studies. We can assume that a PCa that is undetected 
by multiple biopsies will be located at an atypical site, like 
the ventral section. If this is true, it is not surprising that, 
in such a location, cancer will not be detection during 
TURP. The opposite could be true for our population. A 
PCa diagnosed by standard biopsy is most likely located 
in the peripheral zone or the transitional zone and thus it 
might be easier to detect the cancer by the loop during 
transurethral resection.
 Zigeuner et al.  [12] showed that on the basis of both a 
regular DRE and normal PSA levels, the rate of incidental 
PCa detected by TURP was only 7.4%. One would expect 
a higher incidence of PCa in patients with elevated PSA 
levels. This estimation could be supported by our data, 
showing a significantly higher cancer detection rate by 
TURP in patients with PSA levels >10 ng/ml. Bratt  [13] 
postulated that in patients with a symptomatic BPH, a 
standard resection of all adenomatous tissue, including 
the anterior parts, should be performed. In patients with-
out a symptomatic obstruction, the same author discussed 
that it could be an advantage to make a small resection to 
minimize the risk of complications, such as capsular per-
foration and bladder neck sclerosis, which would increase 
the risk of side effects from later radical treatment. In our 
collective, we performed an extended TURP (16.3 g of
32 ml) and found a significant correlation between resect-
ed tissue and cancer detection. The concept of an extend-
ed TURP is different to the previously published literature 
and might be a reason why we detected a much higher 
number of incidences of PCa. Given this significant cor-
relation, we conclude that an extended TURP should be 
performed in conjunction with diagnostic TURP.
 While TURP can frequently detect cancer even in cas-
es with negative biopsies, it may reveal that some of the 
cancers are clinically insignificant, as postulated in a 
study by Kitamura et al.  [14] . They detected small-vol-
ume cancer in 2 of 18 patients who underwent radical 
prostatectomy after TURP (0.49 and 0.36 cm 3 ). In con-
trast to these results, Ornstein et al.  [9] reported that 89% 
of patients positive for cancer by TURP had clinical stage 
T1b or a more extended stage. Niesel et al.  [11] evaluated 
8 patients who underwent radical prostatectomy after de-
tection of PCa by TURP and revealed that none of the 
PCas diagnosed could be considered insignificant.
 Given the fact that some cancers are missed even with 
extended biopsy protocols  [15] , saturation biopsy has 
been explored, resulting in substantial cancer detection 
rates even after negative biopsies  [16] . Although initial 
investigators used regional or general anesthesia, the 
periprostatic block permits routine use in office settings. 
In contrast, TURP must be performed under general or 
spinal anesthesia. Because our cohort included no pa-
tients with previous saturation biopsies, further studies 
have to be performed to compare the efficacy of satura-
tion biopsy with ‘diagnostic TURP’. Perineal template bi-
opsy is another promising technique to identify even 
small PCa lesions. The detection rate of all significant 
cancers (>0.5 cm 3 ) is 98% with this technique that re-
quires anesthesia in all patients  [17] . Today, imaging mo-
dalities such as elastography, histoscanning, MRI and 
others have improved the detection rate of PCa biopsies 
 [18–20] . Therefore the role of TURP in diagnosing PCa 
is even more questionable.
 Another potential shortcoming of TURP repeatedly 
mentioned in the literature is the risk of complicating the 
later radical prostatectomy operation. However, other 
sources claim that radical prostatectomy is only slightly 
more difficult after TURP than routine cases and medium-
term results in terms of continence are fully acceptable.
 Heung et al.  [21] reported the risk of provoking neo-
plastic spreading during TURP by dissemination of PCa 
cells. Similarly, Moreno et al.  [22] reported a hematoge-
nous dissemination of prostate cells caused by transrectal 
biopsy. Although theoretically single tumor cells might 
be disseminated by TURP or prostate biopsy, long-term 
clinical surveys showed no increased amount of tumor 
recurrence or metastasis. Dissemination of tumor cells is 
even reported in radical prostatectomy without inducing 
metastasis  [23] .
 Another interesting aspect of our study is the fact that 
GSs were underestimated by biopsy compared with the 
TURP findings. The biopsy and TURP results only cor-
responded well for the mid-range GSs (4–6), which is why 
nowadays the modified GS system for prostate biopsies 
published in 2003  [24] is used, avoiding the frequent un-
derestimation of GS in biopsies.
 The concept of focal therapy is being given increasing 
consideration with minimally invasive treatment modal-
ities such as HIFU and cryotherapy. Different concepts 
such as hemiablation of the prostate, sparing of lateral 
rims, treatment of an index tumor as well as sparing of the 
urethra are being tested. Our study proved that 65% of the 
patients had PCa within the transitional zone that was 
resected by TURP. With this knowledge, the concept of 
sparing the urethra and its surrounding tissue is problem-
atic at least in an unselected population with limited bi-
opsies like ours.
 There are some shortcomings of our study. One is the 
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back is the fact that the patients did not have repeated 
biopsy or saturation biopsy before TURP because a pre-
selected patient group with known PCa was investigated. 
Also the fact that very inhomogeneous biopsy protocols 
were applied by different referral urologists makes inter-
pretation of our findings more difficult. Because of these 
restrictions, our data do not support a clear recommen-
dation of ‘diagnostic TURP’ as a routine procedure, but 
there is some evidence that TURP might be considered in 
selected patients.
 The cancer detection rate of 65% in patients with pre-
viously known PCa provides some evidence that a ‘diag-
nostic TURP’ can be recommended in some selected pa-
tients with continuously rising PSA level and at least two 
negative biopsies. It remains unclear whether the high de-
tection rate of 65% in patients with previously known PCa 
is some evidence for a ‘diagnostic TURP’ or whether it is 
because the TURP has a much better chance of detecting 
a cancer located in the peripheral zone or the transitional 
zone that was previously detected by a normal prostate 
biopsy.
 One should therefore carefully analyze the biopsy pre-
viously performed and consider if there are still areas not 
sampled that could be reached with transrectal core bi-
opsy before considering a ‘diagnostic TURP’. Because of 
the significant correlation of resected tissue and cancer 
detection, we concluded that an extended TURP should 
be performed if a ‘diagnostic TURP’ is carried out. On the 
other hand, our data show that a focal treatment of the 
prostate gland, sometimes discussed in modern treat-
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